Search the Newsreel

(EXEL) Movement as an Input in Quant Signal Sets

This article analyzes Exelixis Inc. (NASDAQ: EXEL) using quantitative signals and AI models. It identifies weak near-term sentiment but potential for shifts in the mid and long-term outlook, highlighting no resistance levels above the current price. The analysis provides three distinct trading strategies (Position …

Principal Financial Group Inc. Has $45.45 Million Holdings in Helix Energy Solutions Group, Inc. $HLX

Principal Financial Group Inc. reduced its stake in Helix Energy Solutions Group by 2.9% in the first quarter, yet still holds 4.6 million shares valued at approximately $45.45 million. Helix Energy reported first-quarter earnings that matched estimates, with revenue exceeding expectations. Analyst opinions are …

893,824 Shares in Helix Energy Solutions Group, Inc. $HLX Purchased by Bastion Asset Management Inc.

Bastion Asset Management Inc. has acquired a new stake of 893,824 shares in Helix Energy Solutions Group (HLX), valued at approximately $8.58 million, making it their 9th largest holding. The oil and gas company's stock was up 1.1% recentley and opened at $9.54, with …

Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan

Telix Pharmaceuticals has successfully completed the enrollment of patients for its Phase III ProstACT GLOBAL study in Japan, evaluating diagnostic imaging for prostate cancer. This milestone is a crucial step for the company's regulatory submission strategy in Japan. The study focuses on patients with …

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

Telix Pharmaceuticals has announced the completion of patient enrollment in its pivotal Phase 3 registration study for TLX591-Px (Illuccix®) in Japan, targeting prostate cancer imaging. The study, involving 105 patients, aims to evaluate the detection efficacy and safety of 68Ga-PSMA-11 PET/CT in Japanese men …

Telix opens radiopharmaceutical facility in Australia for cancer treatment

Telix Pharmaceuticals has opened a new radiopharmaceutical facility in Melbourne, Australia, to accelerate the development and delivery of cancer treatments. The facility integrates research, manufacturing, and patient treatment services to shorten the time from trials to patient access. It also aims to boost Australia's …

Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment

Telix Pharmaceuticals has started dosing patients in its Phase 2 OPTIMAL-e study, evaluating the next-generation PSMA radioligand therapy TLX597-Tx for metastatic hormone-sensitive prostate cancer. The study, led by Professor Louise Emmett at St Vincent's Hospital Sydney, aims to assess an adaptive treatment strategy to …

What's Driving Exelixis' Recent Momentum and 2026 Outlook

Exelixis is experiencing strong growth driven by its flagship drug Cabometyx, which recently received label expansion into neuroendocrine tumors. The company's next-generation TKI, zanzalintinib, is a critical future asset with potential FDA approval in metastatic colorectal cancer by December 2026 and promising Phase 3 …

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Telix opens Australian-first facility to accelerate delivery of new cancer treatments

Telix Pharmaceuticals has opened a multi-million dollar radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia. This facility is the first of its kind in Australia, integrating radiochemistry laboratories, clinical product manufacturing, patient dose administration, and imaging under one roof. It aims to accelerate …

Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer

Telix Pharmaceuticals, in collaboration with St Vincent’s Hospital Sydney, has dosed the first patients in its Phase 2 OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The trial evaluates TLX597-Tx, a PSMA-targeting radioligand therapy, in combination with standard treatments, aiming to assess its efficacy …

Citi Sees Positive Catalysts for Telix Pharmaceuticals -- Market Talk

Citi maintains a buy rating on Telix Pharmaceuticals, citing several upcoming positive catalysts for the company. These catalysts include the launch of Illuccix in Canada, regulatory submissions in the EU and UK, potential inclusion in the ASX200 index, and the release of new clinical …

Helix Acquisition Corp. III (HLXC) Holds Steady at $10.60 Amid Minimal Movement - ETF Flow

Telix Pharmaceuticals (ASX:TLX) Pulls Back: Is the Healthcare Growth Trade Cooling?

Helix Exploration Raises £17.6m in Oversubscribed Fundraising to Expand Integrated Helium Platform

Is Exelixis (EXEL) Undervalued Or Already Priced In On Its Oncology Growth Story?

Helix Exploration to acquire Keyes helium facility alongside £17.6m fundraising (HEX)

Helix Exploration Launches Discounted Retail Offer to Fund Helium Expansion

Helix Exploration Raises £16 Million in Placing as Major Shareholder Drachs Increases Influence

Elixinol Wellness (ASX:EXL): Can This Wellness Stock Recover After a Tough Run?

Exelixis closes 0.7% below its high as volume improves, while biotech momentum runs hotter

EXEL added 5.5% for the week on 18.2M shares, keeping its 13-week Trend Signal active, but the move comes with valuation distance and a neutral expectancy read.

Felix Gold (ASX:FXG) Drops as Junior Explorers Hit a Rough Patch

Is Helix Energy Solutions Group (HLX) Undervalued As Russell Defensive Index Additions Draw Fresh Fund Flows?

Telix Pharmaceuticals Limited (TLX) heads into June 25 earnings with mixed technical backing

The radiopharmaceuticals developer has risen across recent weekly windows, but relative strength remains negative into the report.

Helix Resources (ASX:HLX): Why Copper Hunters Are Watching This Stock Closely

Should Value Investors Buy Helix Energy Solutions Group (HLX) Stock?

Helix Resources (ASX:HLX): This ASX Copper Explorer Tumbles Today – Here’s WhyHelix Resources (ASX:HLX): This ASX Copper Explorer Tumbles Today – Here’s Why

Telix Pharmaceuticals Limited (TLX) approaches earnings with momentum split

The radiopharmaceuticals developer reports on June 18 with a recent weekly gain set against a weaker four-week tape.

Felix Gold (ASX:FXG) Rallies as Alaska Gold Story Draws Fresh Market Interest

Telix Pharmaceuticals Limited (TLX) enters earnings week with weak relative strength

The oncology radiopharmaceuticals developer has recovered over 12 weeks, but its shorter-term tape remains uneven before the June 18 report.

Helix Energy Solutions (HLX): Buy, Sell, or Hold Post Q1 Earnings?

Unpacking Q1 Earnings: Helix Energy Solutions (NYSE:HLX) In The Context Of Other Oilfield Services Stocks

Felix Gold (ASX:FXG) Gains After Reaching Key Milestone at Antimony Project

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity

Felix Gold (ASX:FXG) Option Exercise Activity Continues Ahead of June 2026 Expiry